Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma.

Trial Profile

Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Treosulfan (Primary) ; Cisplatin; Cytarabine; Dacarbazine; Paclitaxel
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms ChemoSensMM
  • Most Recent Events

    • 19 Oct 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 07 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top